WuXi XDC Inks Pact with IntoCell To Advance ADC Discovery

WuXi XDC announced the signing of a Memorandum of Understanding (MoU) for a comprehensive collaboration in drug-linker technology and CRDMO services spanning from discovery to commercialization.

Dr. Jimmy Li, CEO of WuXi XDC, commented, “IntoCell’s unique drug-linker technologies and our leading, open-access platform are a great combination to enable the fast delivery of pre-clinical candidates, especially in novel ADC programmes. We are delighted to reach this comprehensive partnership with IntoCell and to forge the capability synergy. It demonstrates WuXi XDC’s platform development strategy, namely to grow continually and evolve to help our clients to accelerate and transform the discovery, development and manufacturing of ADCs and other bioconjugates. ” 

Tae Kyo Park, founder and CEO of IntoCell, commented, “Given WuXi XDC’s ample experience and superb capabilities in the CRDMO business, along with IntoCell’s proprietary drug-linker technology, the collaborative efforts of the two companies will pave an easier path for potential ADC development companies to access a variety of drug-linker sets in a stable yet fast-cleavable format. We are eager to witness positive progress towards that goal.”

WuXi XDC Cayman Inc. is a global CRDMO specializing in antibody drug conjugates (ADC) and the larger bioconjugate sector. It offers full-service contract research, development, and production of bioconjugates, including ADCs, as per pharmabiz.

IntoCell has been dedicated to the development of innovative drug-linker technologies since its founding in 2015. The OHPAS linker, for example, can join and release numerous payloads, including phenols.